Literature DB >> 3891122

Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

P Bertault-Pérès, D Maraninchi, Y Carcassonne, J P Cano, J Barbet.   

Abstract

Ciclosporin A (CsA) plasma concentrations were monitored by radioimmunoassay after administration IV and PO to 15 patients before allogeneic bone marrow transplantation. The clearance (10.4 +/- 5.41 1/h), half-life (26.4 +/- 14.6 h), and bioavailability (16% +/- 10%) calculated directly from experimental data showed wide interindividual variations. The kinetics after IV infusion, monitored over 2-5 days, appeared to be triphasic. A three-compartment open mamillary model was thus used to simulate the distribution and elimination kinetics of CsA. The distributive delay between administration PO and absorption in the plasma was approximated using a series of six additional compartments connected with a single transfer rate constant. Then, for each patient, the experimental data corresponding to both IV and PO administration were fitted using a single set of rate constants. Clearance and bioavailability calculated from model parameters correlated well with direct estimations obtained from the areas under the concentration time curves. Drug monitoring and linear modeling will be used in an attempt to achieve stable predetermined plasma concentrations of CsA in bone marrow transplantation patients receiving the drug either IV or PO.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891122     DOI: 10.1007/bf00257300

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

2.  Cyclosporin A is associated with faster engraftment and less mucositis than methotrexate after allogeneic bone marrow transplantation.

Authors:  K Atkinson; J C Biggs; A Ting; A J Concannon; A J Dodds; A Pun
Journal:  Br J Haematol       Date:  1983-02       Impact factor: 6.998

3.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

4.  Conversational SAAM--an interactive program for kinetic analysis of biological systems.

Authors:  R C Boston; P C Greif; M Berman
Journal:  Comput Programs Biomed       Date:  1981 Mar-Jun

5.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

6.  Cyclosporin A: correlation between HPLC and RIA serum levels.

Authors:  E Abisch; T Beveridge; A Gratwohl; W Niederberger; K Nussbaumer; P Schaub; B Speck; M Trapp
Journal:  Pharm Weekbl Sci       Date:  1982-06-25

7.  Intravenous cyclosporine kinetics in renal failure.

Authors:  F Follath; M Wenk; S Vozeh; G Thiel; F Brunner; R Loertscher; M Lemaire; K Nussbaumer; W Niederberger; A Wood
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

9.  Cardiac transplantation with cyclosporin A and prednisone.

Authors:  B P Griffith; R L Hardesty; G M Deeb; T E Starzl; H T Bahnson
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

10.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07
View more
  11 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

3.  Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients.

Authors:  S K Gupta; B Legg; L R Solomon; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

4.  A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

Authors:  A Lindholm; R Dahlqvist; G G Groth; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

5.  Enhancement of etoposide-induced cytotoxicity by cyclosporin A.

Authors:  R Osieka; S Seeber; R Pannenbäcker; D Soll; P Glatte; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing.

Authors:  A Lindholm; S Henricsson; M Lind; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.

Authors:  B Legg; S K Gupta; M Rowland; R W Johnson; L R Solomon
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

10.  Pharmacological Cyclophilin Inhibitors Prevent Intoxication of Mammalian Cells with Bordetella pertussis Toxin.

Authors:  Katharina Ernst; Nina Eberhardt; Ann-Katrin Mittler; Michael Sonnabend; Anna Anastasia; Simon Freisinger; Cordelia Schiene-Fischer; Miroslav Malešević; Holger Barth
Journal:  Toxins (Basel)       Date:  2018-05-01       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.